Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Unraveling the Microenvironment and the Pathogenic Axis of HIF‐1α–Visfatin–Fibrosis in Autoimmune Pancreatitis Using a Single‐Cell Atlas
Zhang, Deyu , Ma, Congjia , Liu, Yanfang , Liu, Zaoqu, Li, Wanshun , Liu, Yue , Wu, Chang , Sun, Liqi , Jiang, Fei , Jiang, Hui , Su, Xiaoju, Peng, Lisi , Wang, Xinyue , Yin, Hua, Wan, Dongling, Zhou, Yuyan , Tian, Xiaorong , Li, Shiyu , Jin, Zhendong , Ji, Baoan , Li, Zhaoshen , Huang, Haojie , Wang, Zhen , Huang, Haojie , Wang, Zhen , Li, Jiayu , Li, Zhaoshen

Advanced Science | January 31, 2025 | Volume: 12 | Issue: 12 | Pages: No page available

10.1002/advs.202412282 | PMID 39887620 Get It

AbstractAutoimmune pancreatitis (AIP) is identified as a severe chronic immune‐related disorder in pancreas, including two subtypes. In this study, pancreatic lesions in patients diagnosed as either type 1 AIP or type 2 AIP are examined, and these patients’ peripheral blood at single‐cell level. Furthermore, flow cytometry, immunofluorescence, and functional assays are performed to verify the identified cell subtypes. In type 1 AIP, there is a notable increase in the amount of B cells and plasma cells, and IgG4+ plasma cells are key pathogenic cells of AIP. The differentiation path of naïve‐stage B cells into IgG4+ produced plasma cells is observed, and an increased amount of T helper cells and T follicular helper (Tfh) cells. This study also reveals that HIF‐1α, an activated transcriptional factor, can directly bind to promoter site of NAMPT, promoting higher levels of visfatin production in HIF1A+ classical monocytes. Pancreatic stellate cells can be activated by extracellular visfatin and promote the development of fibrotic response in pancreatic lesions across both AIP subtypes. The current findings shed light on the exploration of dynamic alterations in peripheral blood cells and cell subgroups in pancreatic lesions of AIP, while elucidating a pathogenic cell subset and potential fibrosis mechanism of AIP.
Cutaneous Manifestations of NAXD or NAXE Deficiency: A Literature Review for the Dermatologist
Abdulkarim, Boraan, Mittal, Setu , Vahidnezhad, Hassan , Davis, Dawn Marie R. , Camilleri, Michael , Aghazadeh, Nessa , Davis, Dawn M R , Aghazadeh Mohandesi, Nessa , Mittal, Setu

Pediatric Dermatology | January 31, 2025 | Volume: 42 | Issue: 2 | Pages: 233-239

10.1111/pde.15868 | PMID 39887790 Get It

ABSTRACT Nicotinamide adenine dinucleotide phosphate hydrate dehydratase (NAXD) and nicotinamide adenine dinucleotide phosphate hydrate epimerase (NAXE) deficiencies are rare autosomal recessive metabolic disorders characterized by severe neurological manifestations during infancy. In affected individuals, febrile illnesses can trigger progressive encephalopathy often accompanied by distinctive skin eruptions, resulting in high mortality rates. This study reviews the literature on NAXD/NAXE deficiencies, focusing on dermatological manifestations and their correlation with genotypic variations and treatment responses. A comprehensive literature search identified 45 patients with 31 pathogenic/likely pathogenic mutations, and a median age of onset at 1.16 years. Patients with NAXE deficiency exhibited a broader range of age of symptom onset compared to those affected with NAXD deficiency. Fever or infections were identified as the most common triggers for decompensation episodes. Skin manifestations were observed in 31% of patients with whole cell NAXD and NAXE deficiencies. The characteristic skin eruption comprises well‐demarcated erythematous and erosive plaques progressing to blistering and necrosis, predominantly affecting flexural surfaces. The mortality rate was 78%, with survivors experiencing varying degrees of neurological sequelae. Niacin/nicotinamide supplementation resulted in improvements in skin lesions and survival rates. The review underscores the critical role of dermatologists in early diagnosis and intervention of NAXE and NAXD deficiencies. Recognizing characteristic skin manifestations is essential, particularly in patients with acute neurological decline following infections or vaccinations. Early intervention with specific supplements shows promise; however, further research is needed to establish standardized treatment protocols and enhance patient outcomes.
Recurrent Intestinal Angioedema with Normal C1-Inhibitor: A Case Report
Jevtic, Dorde , Taylor, Adela, Dumic, Igor , Sviggum, Erik, Nordstrom, Charles W. , Antic, Marina , Dumic, Igor , Jevtic, Djordje , Nordstrom, Charles W , Taylor, Adela

Medicina | January 31, 2025 | Volume: 61 | Issue: 2 | Pages: 245

10.3390/medicina61020245 | PMID 40005362 Get It

Background and Objectives: Angioedema is a non-pitting edema of the submucosal layer which can be acquired or inherited and usually presents with hives. Intestinal angioedema is rare and can mimic other acute gastrointestinal disorders. It is typically associated with a lack or dysfunction of C1-inhibitor, with a small number of cases having normal C1-inhibitor function. We present a rare case of chronic recurrent intestinal angioedema in a patient with normal C1-inhibitor function who did not respond to icatibant therapy. Case presentation: A 56-year-old woman presented with 3 days of abdominal pain, nausea, vomiting, and diarrhea. She denied a history of allergies and reported a 30-year history of similar episodes requiring hospitalization. Initial evaluation demonstrated normal C4 and C1 esterase inhibitor function with negative gastrointestinal bacterial and viral panel. A CT of the abdomen and pelvis demonstrated acute diffuse bowel thickening and prominent mesenteric lymph nodes. MRI demonstrated inflammation of the small and large bowel. EGD and colonoscopy findings were normal. She was diagnosed with intestinal angioedema and started on icatibant without significant improvement. Her symptoms resolved after 3 days of supportive therapy and resolution of inflammation was noted on imaging. She was discharged home with allergy and immunology follow-up. Conclusions: Intestinal angioedema is under-recognized and presentation can overlap with other pathologies of the GI tract. Extensive work up is needed during the first episode of an attack and complement levels should be checked in all patients. Appropriate classification is important as it dictates therapy. However, ambiguous cases like ours sometimes cannot be classified into any specific category.
Nonconventional dysplasia in patients with inflammatory bowel disease and colorectal adenocarcinoma: a case-cohort study
Urquhart, Siri A. , Pallipamu, Namratha, Voruganti, Hima Varsha, Baraskar, Bhavana , Muddaloor, Pratyusha, Sethi, Arshia , Redij, Renisha, Aedma, Keirthana, Gopalakrishnan, Keerthy, Burger, Kelli N. , Kassmeyer, Blake , Lennon, Ryan J. , Sethi, Arshia K , Poigai Arunachalam, Shivaram, Kassmeyer, Blake A., Arunachalam, S P , Arunachalam, Shivaram P. , Mahoney, Douglas W. , Kisiel, John B. , Coelho–Prabhu, Nayantara

Journal of Crohn's and Colitis | January 30, 2025 | Volume: 19 | Issue: 2 | Pages: No page available

10.1093/ecco-jcc/jjaf022 | PMID 39901738 Get It

Abstract Background and Aims Patients with inflammatory bowel disease (IBD) face increased risk of colorectal cancer (CRC). While the natural history of conventional dysplastic precursor lesions has been well-studied, the neoplastic potential of recently described nonconventional (NC) IBD-associated colonic mucosal lesions is unclear. We aimed to assess the incidence of antecedent NC lesions in patients with IBD who developed CRC. Methods A case-cohort study was performed to include patients with a diagnosis of IBD with or without CRC who underwent at least 2 surveillance endoscopic procedures at our institution between 1/1/2007 and 5/31/2023. NC lesions included serrated change and indefinite for dysplasia. Detection rates pre- and post-introduction of high-definition (HD) surveillance colonoscopy were compared. Results In total, 87 patients with IBD and CRC and 200 patients with IBD without CRC were identified. Of the cases, a majority had ulcerative colitis (n = 52, 60%), most commonly with extensive involvement (n = 46, 89%). Conventional (hazard ratio [HR] 2.18, 95% confidence interval [CI] 1.34-3.52) and NC (HR 2.28, 95% CI 1.59-3.26) lesions were associated with increased risk of CRC. Conventional lesions in the post-HD era appeared to have a stronger association with CRC (HR 2.79, 95% CI 1.62-4.77) than NC lesions (HR 1.62, 95% CI 0.86-3.06). Conclusions Both conventional and NC lesions seem to be associated with increased risk of CRC. Conventional lesions are more strongly associated with CRC than NC lesions in the post-HD era, but misclassifications in the pre-HD era may have resulted in a biased increased risk estimate for NC lesions.
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes
Claveau, Jean‐Sébastien , Kapoor, Prashant , Binder, Moritz , Buadi, Francis K. , Cook, Joselle , Dingli, David , Fonder, Amie , Gertz, Morie A. , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L., Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Claveau, Jean-Sebastien , Binder, Moritz , Buadi, Francis K , Cook, Joselle M , Dispenzieri, Angela , Fonder, Amie , Gertz, Morie A , Kourelis, Taxiarchis , Lacy, Martha Q , Leung, Nelson , Warsame, Rahma , Kumar, Shaji K , Dingli, David , Charalampous, Charalampos , Dispenzieri, Angela , Gonsalves, Wilson I. , Hwa, Yi L., Leung, Nelson , Rajkumar, S. Vincent

Blood Advances | January 30, 2025 | Volume: 9 | Issue: 7 | Pages: 1559-1570

10.1182/bloodadvances.2024013355 | PMID 39883947 Get It

Abstract In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs 79 months, P < .05, observed in patients with true solitary plasmacytomas, with no clonal cells in the BM. Risk factors identified for shorter DFS included the presence of clonal plasma cells in the marrow and a difference between involved and uninvolved free light chains of >5 mg/dL. The meta-analysis portion of our study highlighted a male predominance among patients, with a median age of 58 years, and confirmed radiation therapy as the predominant treatment modality. We also found that DFS rates at 3, 5, and 10 years were 66.9%, 55%, and 42.1%, respectively, and noted a significant difference in outcomes between patients with bone and extramedullary plasmacytomas, with the latter group exhibiting better survival rates. This dual-faceted approach provides a thorough overview of survival rates and critical risk factors for patients with plasmacytoma, underscoring the vital role of accurate disease staging at diagnosis and the impact of tumor location on patient prognosis.
Characterization of Factors Associated With Death in Deceased Patients With Mitochondrial Disorders
Ivaniuk, Alina , Anselm, Irina , Bowen, Aaron B. , Cohen, Bruce H. , Eminoğlu, Fatma Tuba , Estrella, Jane , Gallagher, Renata C. , Gannon, Jennifer , Gorman, Gráinne S. , Greene, Carol L. , Haas, Richard , Kapoor, Seema , Karaa, Amel , Koenig, Mary Kay , Kornblum, Cornelia , Lichter‐Konecki, Uta , Lopriore, Piervito , McFarland, Robert , Moe, Aye , Ng, Yi Shiau , Saneto, Russell P. , Scaglia, Fernando , Tarnopolsky, Mark A. , Walker, Melissa , Group, as the Hong Kong Mitochondrial Diseases Interest, Fung, Cheuk Wing , Wong, Tsz-sum, Belaramani, Kiran , Chan, Chun-kong , Chan, Wing-ki, Chan, Wai-lun Larry, Cheung, H. M. E., Cheung, Ka-yin, Chang, Richard Shek‐kwan , Cheung, Sing-ngai, Cheung, Tsz-Fung, Cheung, Yuk-fai, Chong, Shuk-ching Josephine, Chow, Chi-kwan Jasmine , Fan, Florence , Fok, Wai-ming Joshua , Fung, Tsui-hang Sharon , Hui, Kwok-fai, Hui, Ting-hin, Ko, Chun Hung, Kwan, Min-chung, Kwok, Anne Mei Kwun , Kwok, Sung-shing Jeffrey, Lai, Moon-sing, Lam, Yau-on, Lam, Ching‐Wan , Lau, Ming-chung, Law, Hiu-Fung, Lee, Wing‐Cheong , Leung, Kin-hang, Leung, Kit-yan, Li, Siu-hung, Ling, Tsz-ki, Liu, Kam Tim , Lui, Colin H. T., Luk, Ching-on, Luk, Ho‐Ming , Ma, Che-Kwan, Ma, Karen , Ma, Kam-hung , Mew, Yuen-ni, Mo, Alex, Hg, Sui-Fun, Poon, Grace Wing-kit , Sheng, Bun , Szeto, Cheuk-ling Charing, Tai, Shuk‐Mui, Tang, Jing-Liang, Tse, Choi-ting Alan , Tsung, Li-yan Lilian, Wong, Ho-ming June, Wong, Wing-yin Winnie, Wong, Kwok-kui, Wong, Suet-na Sheila , Wong, Chun-nei Virginia, Wong, Wai-shan Sammy, Wong, Chi-kin Felix, Wu, Shun-Ping, Wu, Hiu-fung Jerome , Yau, Man-Mut, Yau, Eric Kin Cheong , Yeung, Wai Lan , Yeung, Hon‐Ming Jonas , Yip, Kin-keung Edwin, Young, Pui-hong Terence, Yuan, Gao , Yuen, Yuet‐Ping , Yuen, Chi-lap, Anselm, Irina A , Bowen, Aaron , Ganetzky, Rebecca D , Gannon, Jennifer , Gorman, Grainne S , Greene, Carol , Gropman, Andrea L , Haas, Richard H , Hirano, Michio , Kapoor, Seema , Karaa, Amel , Koenig, Mary Kay , Kornblum, Cornelia , Kose, Engin , Larson, Austin A , Lichter-Konecki, Uta , Lopriore, Piervito , Mancuso, Michelangelo , McFarland, Robert , Moe, Aye Myat , Ng, Yi Shiau , Saneto, Russell P , Scaglia, Fernando , Sue, Carolyn M , Tarnopolsky, Mark , Walker, Melissa A , Parikh, Sumit , Cheuk-Wing, Fung , Wong, Tsz-Sum , Belaramani, Kiran , Chan, Chun-Kong , Chan, Wing-Ki , Chan, Wai-Lun Larry , Cheung, Hon-Wing , Cheung, Ka-Yin , Chang, Shek-Kwan , Cheung, Sing-Ngai , Cheung, Tsz-Fung , Cheung, Yuk-Fai , Chow, Chi-Kwan Jasmine , Chung, Hon-Yin B , Fan, Sin-Ying Florence , Fok, Wai-Ming Joshua , Fung, Tsui-Hang Sharon , Hui, Kwok-Fai , Hui, Ting-Hin , Hui, Joannie , Ko, Chun Hung , Kwan, Min-Chung , Kwok, Mei-Kwan Anne , Kwok, Sung-Shing Jeffrey , Lai, Moon-Sing , Lam, Yau-On , Lam, Ching-Wan , Lau, Ming-Chung , Law, Chun-Yiu Eric , Law, Hiu-Fung , Lee, Wing-Cheong , Leung, Kin-Hang , Leung, Kit-Yan , Li, Siu-Hung , Liu, Kam-Tim Timothy , Lo, Fai-Man , Lui, Colin , Luk, Ho-Ming , Ma, Che-Kwan , Ma, Karen , Ma, Kam-Hung , Mo, Alex , Hg, Sui-Fun , Poon, Wing-Kit Grace , Sheng, Bun , Tse, Choi-Ting Alan , Wong, Ho-Ming June , Wong, Wing-Yin Winnie , Wong, Kwok-Kui , Wong, Suet-Na Sheila , Wong, Chun-Nei Virginia , Wong, Wai-Shan Sammy , Wu, Hiu-Fung Jerome , Yau, Kin-Cheong Eric , Yeung, Wai-Lan , Yeung, Hon-Ming Jonas , Yip, Kin-Keung Edwin , Young, Pui-Hong Terence , Yuan, Gao , Yuen, Yuet-Ping Liz , Ivaniuk, Alina , Cohen, Bruce H , Ganetzky, Rebecca , Larson, Austin , Morava, Éva , Sue, Carolyn M. , Parikh, Sumit , Group, as the Hong Kong Mitochondrial Diseases Interest, Fong, Ka-Wing, Lee, Han‐Chih Hencher , Tang, Jing-Liang, Wu, Hui-Jun

Neurology | January 30, 2025 | Volume: 104 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000209779 | PMID 39883904 Get It

AugGPT: Leveraging ChatGPT for Text Data Augmentation
Dai, Haixing , Liu, Zhengliang , Liao, Wenxiong , Huang, Xiaoke , Wu, Zihao , Zhao, Lin , Xu, Shaochen , Zeng, Fang , Liu, Wei , Liu, Ninghao , Shen, Dinggang, Liu, Tianming , Li, Xiang , Liu, Wei , Cao, Yihan , Li, Sheng , Zhu, Dajiang , Cai, Hongmin , Sun, Lichao , Li, Quanzheng , Shen, Dinggang G. , Li, Xiang , Wu, Zihao , Zhao, Lin

IEEE Transactions on Big Data | January 30, 2025 | Volume: 11 | Issue: 3 | Pages: 907-918

10.1109/tbdata.2025.3536934 Get It

Revised Process for ACNS Guidelines Development
Andrade, Edgard , Galloway, Gloria, Hyslop, Ann , Selioutski, Olga , Arnold, Susan T., Drislane, Frank W. , Gloss, David , Marashly, Ahmad , Nuwer, Mark R., Sabau, Dragos , Shahid, Asim, Tatum, William O. , Vengrow, Michael, Wusthoff, Courtney J. , Quraishi, Imran H , Andrade, Edgard , Wusthoff, Courtney J , Selioutski, Olga , Hyslop, Ann , Sinha, Saurabh Kumar , Arnold, Susan T., Arya, Ravindra , Bagić, Anto , Hani, Abeer J. , Kobayashi, Eliane , Park, Jun , San‐Juan, Daniel , Shahid, Asim, Skjei, Karen L. , Vengrow, Michael

Journal of Clinical Neurophysiology | January 30, 2025 | Volume: 42 | Issue: 2 | Pages: 95-100

10.1097/wnp.0000000000001133 | PMID 39883486 Get It

Summary: The development of clinical practice guidelines is an evolving field. In response to the need for consistent, evidence-based medical practice, the American Clinical Neurophysiology Society identified the need to update the Society's guideline development process. The American Clinical Neurophysiology Society Guidelines Committee created an action plan with the goal of improving transparency and rigor for future guidelines and bringing existing guidelines to current standards. This article provides an overview of the new American Clinical Neurophysiology Society standards for the creation of clinical guidance documents, including clinical guidelines, technical standards, and consensus statements. This process is rooted in the importance of clinical guidance documents and their significance in the context of current behests for updated standards for practicing clinical neurophysiology. The need and rationale for updating the guideline development process from its prior state were described. The updated American Clinical Neurophysiology Society categories for clinical guidance and recommendations were defined and compared. Finally, the new process is summarized, focusing on methodologies, authorship, and conflicts of interest.
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Jacobson, Caron A. , Nikiforow, Sarah , Ahmed, Sairah , Miklos, David B. , Lin, Yi , Lunning, Matthew A. , Hill, Brian T. , Ghobadi, Armin , Hu, Zhen‐Huan , Hemmer, Michael, Zoratti, Michael J. , Vunnum, Suresh, Tsang, Jonathan , Spooner, Clare, Smith, Harry , Fu, Christine, Patel, Anik R. , Miao, Harry , Shahani, Shilpa, Mirjah, Debbie L., Xu, Hairong , Pasquini, Marcelo C. , Ahmed, Sairah , Miklos, David B , Ghobadi, Armin , Zoratti, Michael J , Pasquini, Marcelo , Locke, Frederick L. , Siddiqi, Tanya

Blood Advances | January 30, 2025 | Volume: 9 | Issue: 11 | Pages: 2663-2676

10.1182/bloodadvances.2024013656 | PMID 39883946 Get It

Abstract Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel. The impact of V2Vt (<28 days vs ≥28 to <40 days vs ≥40 days) on effectiveness and safety outcomes was evaluated in patients treated with axi-cel enrolled in a post-authorization safety study using the Center for International Blood and Marrow Transplant Research data. SLR and meta-analysis showed that patients treated with axi-cel had the shortest median V2Vt (30.6 days) compared with tisa-cel (48.4 days) or liso-cel (35.9 days). Real-world analysis of patients treated with axi-cel demonstrated that V2Vt ≥40 days was associated with significantly lower complete response rate than V2Vt <28 days (odds ratio [OR], 0.61) or ≥28 to <40 days (OR, 0.66) and significantly worse overall survival than V2Vt <28 days (hazard ratio [HR], 1.33) or ≥28 to <40 days (HR, 1.36). Higher prolonged thrombocytopenia rates were observed in patients with axi-cel V2Vt ≥28 to <40 days or ≥40 days compared with <28 days (OR, 1.44 or 1.95, respectively). Together, these results show the impact of V2Vt on patient outcomes with axi-cel therapy and that earlier infusion with CD19-CAR therapies may be beneficial.
Enhancing patient engagement and understanding: is providing direct access to laboratory results through patient portals adequate?
Lustria, Mia Liza A. , Aliche, Obianuju, He, Zhe , Killian, Michael O , He, Zhe

JAMIA Open | January 30, 2025 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/jamiaopen/ooaf009 | PMID 40130170 Get It

Abstract Objectives To explore patients’ use of patient portals to access lab test results, their comprehension of lab test data, and factors associated with these. Materials and Methods An online survey was administered to 276 adults 18+ years. Multivariate logistic regression was used to determine factors associated with patient portal use to view lab test results and lab test comprehension. Results The sample was predominantly White (72.5%), female (55.4%), with mean age 50.7 ± 15.5 years. Overall, participants had low numeracy (10.79 ± 2.71) and eHealth literacy skills (23.91 ± 5.29), and moderate lab test comprehension scores (18 ± 2.3). White participants with greater eHealth literacy were more likely to access lab test results via patient portals, whereas those with a college education were less likely to do so (χ2 [3]=31.23, P < .001). The regression showed that older age, fewer chronic conditions, and use of patient portals were significantly related to higher lab test comprehension scores (F [22, 250]=8.73, P <.001). Older adults performed better on comprehension tests but reported having difficulty understanding lab tests, expressing a preference for their doctors to explain them. Discussion The findings shed light on the experiences and needs of different user groups that must be addressed to enhance their ability to effectively use patient portals for obtaining lab test results. Conclusion More research is needed to determine patient barriers to comprehending lab test results online and to develop tailored strategies to improve patients’ self-efficacy to meaningfully use medical information in patient portals.